RETINAL SOLUTIONS LLC

Biotech · Private

Noregen, a norrin-derived growth factor therapeutic delivered via intravitreal injection to regenerate retinal blood vessels in ischemic retinopathies

Grants
$1.7M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
15
9 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Noregen(TM), a regenerative medicine ocular therapeutic$227,051
Federal grantDepartment of Health and Human Services · Phase II · Noregen, a regenerative medicine ocular therapeutic$717,783
Federal grantDepartment of Health and Human Services · Phase II · Noregen, a regenerative medicine ocular therapeutic$720,183
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2846Lomond Therapeutics——
2847Cardurion Pharmaceuticals—$350M
2848DIGITAL NANOGENETICS, LLC——
2849RETINAL SOLUTIONS LLC——
2850Stipple Bio—$87M
2851PPI PHARMACEUTICALS, LLC——
2852YOLO IMMUNE INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 9 granted of 15

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.